BACKGROUND AND PURPOSE: The prevalence of antiplatelet drug resistance among patients who undergo cerebrovascular stent placement is unknown. We aimed to assess the feasibility of monitoring antiplatelet drug effects in a single-center cohort undergoing cerebrovascular stent placement. MATERIALS AND METHODS: We prospectively collected medical, laboratory, and radiographic data on patients who underwent cerebrovascular stent placement. We used the rapid platelet function assay-aspirin (RPFA-ASA) to calculate aspirin reaction units (ARU) and the P2Y12 assay to calculate P2Y12 reaction units and percentage platelet inhibition. Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%. RESULTS: Among 76 patients, stent indications were the following: wide-neck aneurysm (57, 75.0%), symptomatic intracranial stenosis (12, 15.7%), carotid stenosis (5, 6.6%), and vertebral stenosis (2, 2.6%). For aspirin, the median dosage per week was 1300 mg and median ARU was 410. Among 71 patients on aspirin, 3 patients (4.2%) were resistant; there was a significant inverse correlation between aspirin dose and ARU (r = -0.31, P = .01). Among 55 patients on clopidogrel, the median dosage per week was 525 mg with a mean platelet inhibition of 43.2%. Twenty-eight patients (51.9%) were clopidogrel-resistant. In a multivariable linear regression model, age older than 55 years (b = -16.3, P = .020) and diabetes (b = -26.8, P = .015) were inversely related to percentage platelet inhibition. CONCLUSIONS: Using point-of-care tests, we found that aspirin resistance is relatively uncommon, whereas clopidogrel resistance occurred in half of patients undergoing cerebrovascular stent placement. Further studies should focus on ideal doses, timing, and duration of antiplatelet therapy for cerebrovascular stent placement.
BACKGROUND AND PURPOSE: The prevalence of antiplatelet drug resistance among patients who undergo cerebrovascular stent placement is unknown. We aimed to assess the feasibility of monitoring antiplatelet drug effects in a single-center cohort undergoing cerebrovascular stent placement. MATERIALS AND METHODS: We prospectively collected medical, laboratory, and radiographic data on patients who underwent cerebrovascular stent placement. We used the rapid platelet function assay-aspirin (RPFA-ASA) to calculate aspirin reaction units (ARU) and the P2Y12 assay to calculate P2Y12 reaction units and percentage platelet inhibition. Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%. RESULTS: Among 76 patients, stent indications were the following: wide-neck aneurysm (57, 75.0%), symptomatic intracranial stenosis (12, 15.7%), carotid stenosis (5, 6.6%), and vertebral stenosis (2, 2.6%). For aspirin, the median dosage per week was 1300 mg and median ARU was 410. Among 71 patients on aspirin, 3 patients (4.2%) were resistant; there was a significant inverse correlation between aspirin dose and ARU (r = -0.31, P = .01). Among 55 patients on clopidogrel, the median dosage per week was 525 mg with a mean platelet inhibition of 43.2%. Twenty-eight patients (51.9%) were clopidogrel-resistant. In a multivariable linear regression model, age older than 55 years (b = -16.3, P = .020) and diabetes (b = -26.8, P = .015) were inversely related to percentage platelet inhibition. CONCLUSIONS: Using point-of-care tests, we found that aspirin resistance is relatively uncommon, whereas clopidogrel resistance occurred in half of patients undergoing cerebrovascular stent placement. Further studies should focus on ideal doses, timing, and duration of antiplatelet therapy for cerebrovascular stent placement.
Authors: Adnan Kastrati; Nicolas von Beckerath; Alexander Joost; Gisela Pogatsa-Murray; Olga Gorchakova; Albert Schömig Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Paul A Gurbel; Kevin P Bliden; Kevin M Hayes; Jason A Yoho; William R Herzog; Udaya S Tantry Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry Journal: J Am Coll Cardiol Date: 2005-10-21 Impact factor: 24.094
Authors: David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya Journal: Pharm Res Date: 2010-07-14 Impact factor: 4.200
Authors: N Flechtenmacher; F Kämmerer; R Dittmer; U Budde; P Michels; J Röther; B Eckert Journal: AJNR Am J Neuroradiol Date: 2015-08-13 Impact factor: 3.825
Authors: Wiebke Kurre; Friedhelm Brassel; Roland Brüning; Jan Buhk; Bernd Eckert; Susanna Horner; Michael Knauth; Thomas Liebig; Jana Maskova; Dirk Mucha; Vojtech Sychra; Matthias Sitzer; Michael Sonnberger; Marc Tietke; Johannes Trenkler; Bernd Turowski; Joachim Berkefeld Journal: Neuroradiology Date: 2011-01-11 Impact factor: 2.804
Authors: M Lin; M Todaro; J Chan; L Churilov; W S Zhu; S Ramdave; P J Mitchell; R J Dowling; P Kwan; B Yan Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825